MINIREVIEWS

877  Oncologic aspects of the decision-making process for surgical approach for colorectal liver metastases progressing during chemotherapy
Araujo RLC, Carvalho CGCY, Maeda CT, Milani JM, Bugano DG, de Moraes PHZ, Linhares MM

887  Research progress on the immune microenvironment of the gallbladder in patients with cholesterol gallstones

ORIGINAL ARTICLE

Retrospective Study

896  Central pancreatectomy for benign or low-grade malignant pancreatic tumors in the neck and body of the pancreas

904  Irinotecan- vs oxaliplatin-based regimens for neoadjuvant chemotherapy in colorectal liver metastasis patients: A retrospective study

918  Predictors of difficult endoscopic resection of submucosal tumors originating from the muscularis propria layer at the esophagogastric junction
Wang YP, Xu H, Shen JX, Liu WM, Chu Y, Duan BS, Lian JJ, Zhang HB, Zhang L, Xu MD, Cao J

930  Liver transplantation with simultaneous splenectomy increases risk of cancer development and mortality in hepatocellular carcinoma patients
Fan HL, Hsieh CB, Kuo SM, Chen TW

940  Development of an innovative nomogram of risk factors to predict postoperative recurrence of gastrointestinal stromal tumors
Guan SH, Wang Q, Ma XM, Qiao WJ, Li MZ, Lai MG, Wang C

950  Comparison of short-term efficacy between totally laparoscopic gastrectomy and laparoscopic assisted gastrectomy for elderly patients with gastric cancer
Zhao RY, Li HH, Zhang KC, Cui H, Deng H, Gao JW, Wei B

963  Personal predictive model based on systemic inflammation markers for estimation of postoperative pancreatic fistula following pancreaticoduodenectomy

976  Feasible management of median arcuate ligament syndrome in orthotopic liver transplantation recipients
Li SX, Fan YH, Tian GY, Lv GY
## Contents

**World Journal of Gastrointestinal Surgery**

**Monthly Volume 14 Number 9 September 27, 2022**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>986</td>
<td>Study of preoperative diagnostic modalities in Chinese patients with superficial esophageal squamous cell carcinoma</td>
</tr>
<tr>
<td>997</td>
<td>Oesophageal cancer metastases: An observational study of a more aggressive approach</td>
</tr>
<tr>
<td>1008</td>
<td>Change of tumor-infiltrating lymphocyte of associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma</td>
</tr>
<tr>
<td>1026</td>
<td>Blood index panel for gastric cancer detection</td>
</tr>
<tr>
<td>1037</td>
<td>Effect of cardiac output - guided hemodynamic management on acute lung injury in pediatric living donor liver transplantation</td>
</tr>
<tr>
<td>1049</td>
<td>Minimally invasive endoscopic repair of rectovaginal fistula</td>
</tr>
<tr>
<td>1060</td>
<td>Laparoscopic appendectomy, stump closure and endoloops: A meta-analysis</td>
</tr>
<tr>
<td>1072</td>
<td>Retrorectal mucinous adenocarcinoma arising from a tailgut cyst: A case report and review of literature</td>
</tr>
<tr>
<td>1082</td>
<td>Successful treatment of acute symptomatic extensive portal venous system thrombosis by 7-day systemic thrombolysis</td>
</tr>
<tr>
<td>1086</td>
<td>Prediction factors for ischemia of closed-loop small intestinal obstruction</td>
</tr>
</tbody>
</table>

**Authors**

- Zeng YT, Sun YY, Tan WC, Luo SA, Zou BH, Luo GY, Huang CY
- Pickett L, Dunne M, Monaghan O, Grogan L, Breathnach O, Walsh TN
- Guo GH, Xie YB, Zhang PJ, Jiang T
- Zeng YX, He YH, Jiang Y, Jia F, Zhao ZT, Wang XF
- Gao FB, Wang L, Zhang WX, Shao XD, Guo XZ, Qi XS
- Pavlidis ET, Pavlidis TE
ABOUT COVER
Editorial Board Member of World Journal of Gastrointestinal Surgery, Shu-You Peng, FACS, FRCP (Hon), MD, Full Professor, Department of Surgery, Medical School of Zhejiang University, Hangzhou 310009, Zhejiang Province, China. zrwkpsy@zju.edu.cn

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Surgery (WJGS, World J Gastrointest Surg) is to provide scholars and readers from various fields of gastrointestinal surgery with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGS mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal surgery and covering a wide range of topics including biliary tract surgical procedures, biliopancreatic diversion, colectomy, esophagectomy, esophagostomy, pancreas transplantation, and pancreatectomy, etc.

INDEXING/ABSTRACTING
The WJGS is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJGS as 2.505; IF without journal self cites: 2.473; 5-year IF: 3.099; Journal Citation Indicator: 0.49; Ranking: 104 among 211 journals in surgery; Quartile category: Q2; Ranking: 81 among 93 journals in gastroenterology and hepatology; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Rui-Rui Wu; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL
World Journal of Gastrointestinal Surgery

ISSN
ISSN 1948-9366 (online)

LAUNCH DATE
November 30, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Peter Schemmer

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
September 27, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com
Successful treatment of acute symptomatic extensive portal venous system thrombosis by 7-day systemic thrombolysis

Fang-Bo Gao, Le Wang, Wen-Xiu Zhang, Xiao-Dong Shao, Xiao-Zhong Guo, Xing-Shun Qi

Specialty type: Gastroenterology and hepatology
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind
Peer-review report’s scientific quality classification
Grade A (Excellent): A
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Dasuqi SA, Saudi Arabia; El-Karaksy H, Egypt
Received: April 29, 2022
Peer-review started: April 29, 2022
First decision: May 29, 2022
Revised: June 1, 2022
Accepted: August 15, 2022
Article in press: August 15, 2022
Published online: September 27, 2022

Abstract
Acute portal venous system thrombosis (PVST) can cause acute mesenteric ischemia and even intestinal infarction, which are potentially fatal, and requires recanalization in a timely fashion. Herein, we report a 56-year-old man with acute non-cirrhotic symptomatic extensive PVST who achieved portal vein recanalization after systemic thrombolysis combined with anticoagulation. Initially, anticoagulation with enoxaparin sodium for 4 d was ineffective, and then systemic thrombolysis for 7 d was added. After that, his abdominal pain completely disappeared, and portal vein system vessels became gradually patent. Long-term anticoagulation therapy was maintained. In conclusion, 7-d systemic thrombolysis may be an effective and safe choice of treatment for acute symptomatic extensive PVST which does not respond to anticoagulation therapy.

Key Words: Portal vein; Mesenteric vein; Thrombosis; Thrombolysis; Anticoagulation; Deep vein thrombosis

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The present case suggests that systemic thrombolysis should be safe and effective for acute extensive portal venous system thrombosis, if it is unresponsive to anticoagulation.
Acute portal venous system thrombosis (PVST) is potentially life-threatening and can achieve a good response to agitation thrombolysis combined with catheter-directed thrombolysis[1]. However, it should be acknowledged that systemic thrombolysis, a more convenient treatment approach, has been rarely attempted for the treatment of acute PVST in clinical practice due to its potential bleeding risk. Herein, we report a case of acute symptomatic extensive PVST successfully treated by systemic thrombolysis combined with anticoagulation to strengthen our confidence in its clinical efficacy and safety.

A 56-year-old man with a history of hepatitis B virus infection was admitted to the Department of Gastroenterology due to aggravating severe epigastric pain for nearly half a month. He had no other obvious medical history. On physical examinations, his abdomen was soft without abdominal tenderness, rebound, or tension. On day 1 of admission, laboratory tests were performed (Table 1). Contrast-enhanced computed tomography (CT) showed no contrast agent filling within all vessels of the portal venous system, including the main portal vein (MPV), right portal vein (RPV), left portal vein (LPV), confluence of the superior mesenteric vein (SMV) and splenic vein (SV), SMV, and SV (Figure 1A), suggesting a diagnosis of occlusive PVST. Thus, subcutaneous injection of enoxaparin sodium was immediately initiated at a dose of 5000 IU (62.5 IU/kg) twice daily. On day 5, his abdominal pain was not relieved. Anti-Xa level was 0.05 IU/mL (reference range: 0-0.1 IU/mL). Contrast-enhanced CT showed no significant improvement of PVST (Figure 1B). Thus, systemic thrombolysis was recommended. After obtaining this patient and his relatives’ informed consent, intravenous injection of urokinase at a dose of 300000 IU twice daily was added on subcutaneous injection of enoxaparin sodium at a dose of 5000 IU twice daily. On day 10, this patient’s abdominal pain improved significantly. Contrast-enhanced CT showed that MPV, LPV, and RPV thromboses were partially recanalized (Figure 1C). On day 12, urokinase was discontinued. No bleeding event occurred during the period of systemic thrombolysis. On day 17, his abdominal pain completely disappeared. Then, he was discharged. Enoxaparin sodium was replaced with oral rivaroxaban 20 mg once daily. After 5-mo anticoagulation with rivaroxaban, contrast-enhanced CT showed that the SMV and SV became patent and fine collateral vessels developed around the RPV without signs of esophageal varices (Figure 1D). Laboratory tests were performed again (Table 1). At the time of writing this paper, rivaroxaban is still continued.

Anticoagulation is the preferred choice of treatment for acute PVST[2], but 18% of patients still develop transmural intestinal necrosis after anticoagulation therapy, and 25%-50% will develop prehepatic portal hypertension[3,4]. Patients with acute PVST who do not respond to anticoagulation therapy may benefit from thrombolytic therapy[5]. However, thrombolytic therapy has a higher risk of bleeding, including upper gastrointestinal bleeding, abdominal bleeding, and epistaxis. Notably, the current evidence on systemic thrombolytic therapy for PVST is scarce. In a retrospective cohort study[6], 33 patients with acute PVST were treated with intravenous injection of 750000 IU/d streptokinase or 100-150 mg/6-12 h recombinant tissue-type plasminogen activator (rt-PA) for 2-3 d, followed with heparin infusion, and then received oral anticoagulants for 12 mo after discharge. Thrombosis recanalization was achieved in 23 patients. In a prospective cohort study[7], nine cirrhotic patients with recent PVST received continuous intravenous infusion of rt-PA at a dose of 0.25 mg/kg/d combined with subcutaneous injection of low molecular weight heparin for a maximum duration of 7 d. Thrombosis recanalization was achieved in eight patients. Besides, a stepwise thrombolysis regimen for PVST should be considered. In a study by Benmassaoud et al[8], 22 non-cirrhotic patients with acute PVST received systemic thrombolysis, of whom eight achieved portal vein recanalization, and the remaining 14 did not have any improvement of thrombosis or abdominal pain and were then treated with transjugular intrahepatic portosystemic shunt (TIPS) or local thrombolysis. Finally, the overall rate of portal vein recanalization was 86.4%. Notably, local thrombolysis and TIPS were employed in the study by Benmassaoud et al[8], but they are more invasive and technically complicated as compared to systemic thrombolysis. In our case, initial anticoagulation was less effective, and thus systemic thrombolysis was given. The symptoms improved significantly after thrombolysis, which avoided further vascular interventional procedures, and even surgery for intestinal infarction and necrosis[9].

Acute PVST is often defined if PVST develops 1-3 wk since the onset of symptoms. Accordingly, our case should be diagnosed with acute PVST. Notably, the timing of antithrombotic therapy for acute PVST is very important. A shorter interval from the diagnosis of PVST to initiation of antithrombotic therapy indicates a higher probability of thrombus recanalization[10]. In our case, the interval was...
Table 1 Laboratory tests in this patient

<table>
<thead>
<tr>
<th>Laboratory tests</th>
<th>Reference range</th>
<th>Before antithrombotic treatment</th>
<th>After 7-d thrombolysis</th>
<th>After 5-mo oral anticoagulants</th>
</tr>
</thead>
<tbody>
<tr>
<td>White blood cell count (10⁹/L)</td>
<td>3.5-9.5</td>
<td>9.70</td>
<td>5.20</td>
<td>6.7</td>
</tr>
<tr>
<td>Hemoglobin (g/L)</td>
<td>130-175</td>
<td>143</td>
<td>119</td>
<td>164</td>
</tr>
<tr>
<td>Platelet count (10⁹/L)</td>
<td>125-350</td>
<td>230</td>
<td>242</td>
<td>123</td>
</tr>
<tr>
<td>Total bilirubin (μmol/L)</td>
<td>5.1-22.2</td>
<td>16.70</td>
<td>8.1</td>
<td>13.9</td>
</tr>
<tr>
<td>Aspartate aminotransferase (U/L)</td>
<td>15-40</td>
<td>17.60</td>
<td>16.29</td>
<td>18.65</td>
</tr>
<tr>
<td>Alanine aminotransferase (U/L)</td>
<td>9-50</td>
<td>20.39</td>
<td>20</td>
<td>21.99</td>
</tr>
<tr>
<td>International normalized ratio</td>
<td>0.9-1.2</td>
<td>1.19</td>
<td>1.15</td>
<td>0.99</td>
</tr>
<tr>
<td>Prothrombin time (s)</td>
<td>11.0-13.7</td>
<td>14.80</td>
<td>14.4</td>
<td>13.1</td>
</tr>
<tr>
<td>Activated partial thromboplastin time (s)</td>
<td>31.5-43.5</td>
<td>32.30</td>
<td>38.9</td>
<td>34.6</td>
</tr>
<tr>
<td>D-dimer (mg/L)</td>
<td>0-0.55</td>
<td>7.71</td>
<td>4.77</td>
<td>0.27</td>
</tr>
<tr>
<td>Antithrombin III (%)</td>
<td>80-120</td>
<td>48</td>
<td>-</td>
<td>55</td>
</tr>
<tr>
<td>Fibrinogen (g/L)</td>
<td>2.0-4.0</td>
<td>3.09</td>
<td>4.87</td>
<td>3.09</td>
</tr>
<tr>
<td>Protein C (%)</td>
<td>70-140</td>
<td>-</td>
<td>-</td>
<td>89.3</td>
</tr>
<tr>
<td>Protein S (%)</td>
<td>75-130</td>
<td>-</td>
<td>-</td>
<td>90.4</td>
</tr>
</tbody>
</table>

Figure 1 Axial and coronal computed tomography images in this patient. A: On day 1 of admission, computed tomography (CT) images demonstrated occlusive thrombosis within the main portal vein (MPV), left portal vein (LPV), right portal vein (RPV), confluence of the superior mesenteric vein (SMV) and splenic vein (SV), SMV, and SV, with fine collaterals around the hilum (red arrow); B: On day 5, CT images demonstrated partially recanalized LPV and RPV (red arrow); C: On day 10, CT images demonstrated partially recanalized MPV, LPV, and RPV (red arrow); D: After 5-mo anticoagulation with rivaroxaban, CT images demonstrated completely recanalized SMV and SV (red arrow).

relatively long, which potentially compromised the efficacy of anticoagulation and forced the use of systemic thrombolysis.

In conclusion, systemic thrombolysis should be considered in the cases where anticoagulant therapy fails and interventional therapy is neither available nor feasible. The timing of systemic thrombolytic
therapy and the dose of thrombolytic drugs should be further explored.

FOOTNOTES

Author contributions: Qi XS conceived this manuscript; Zhang WX, Guo XZ, and Qi XS treated this case; Gao FB, Wang L, and Qi XS followed this case; Gao FB and Qi XS drafted the manuscript; Gao FB, Wang L, Zhang WX, Shao XD, Guo XZ, and Qi XS revised the manuscript; all authors have made an intellectual contribution to the manuscript and approved the submission.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Xiao-Zhong Guo 0000-0002-6397-0501; Xing-Shun Qi 0000-0002-9448-6739.

S-Editor: Fan JR
L-Editor: Wang TQ
P-Editor: Fan JR

REFERENCES
